Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. - Common Stock (NQ:HELP)

12.59 -0.02 (-0.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 981,695
Open 12.50
Bid (Size) 12.56 (1,200)
Ask (Size) 12.60 (300)
Prev. Close 12.61
Today's Range 12.09 - 12.78
52wk Range 3.760 - 15.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression ↗
Helus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of... 
Via MarketBeat
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Annual and Special Meeting Results, Legal Name Change Effective Oct. 1
Via Investor Brand Network

Performance

YTD
+62.9%
+62.9%
1 Month
+3.4%
+3.4%
3 Month
+83.0%
+83.0%
6 Month
+191.4%
+191.4%
1 Year
+62.9%
+62.9%

More News

Read More
News headline image
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
From Helus Pharma
Via GlobeNewswire
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in TD Cowen Neuropsychiatry Summit
Via Investor Brand Network
TinyGemsBreaks – Helus Pharma (TM) (NASDAQ: HELP) (Cboe CA: HELP) Advances HLP003 Phase 3 Program, Targets Q4 2026 Topline Data
Via Investor Brand Network
News headline image
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board ↗
Via MarketBeat
News headline image
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Presents HLP003 Data From MDD Program at Psych Congress 2026
Via Investor Brand Network
News headline image
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
From Helus Pharma
Via GlobeNewswire
News headline image
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 ↗
Via MarketBeat
News headline image
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances ↗
Via MarketBeat
BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Morgan Stanley Global Healthcare Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Cantor Global Healthcare Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Regina Donohue Chief People Officer and Suresh Durgam to Scientific Advisory Board
Via Investor Brand Network
News headline image
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
From Helus Pharma
Via GlobeNewswire
News headline image
Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003 ↗
Via MarketBeat
Topics Intellectual Property
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Canaccord Genuity Growth Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
From Helus Pharma
Via GlobeNewswire
News headline image
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
From USA News Group
Via GlobeNewswire
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Michael Halstead as CEO
Via Investor Brand Network

Frequently Asked Questions

Is Cybin Inc. - Common Stock publicly traded?
Yes, Cybin Inc. - Common Stock is publicly traded.
What exchange does Cybin Inc. - Common Stock trade on?
Cybin Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cybin Inc. - Common Stock?
The ticker symbol for Cybin Inc. - Common Stock is HELP on the Nasdaq Stock Market
What is the current price of Cybin Inc. - Common Stock?
The current price of Cybin Inc. - Common Stock is 12.59
When was Cybin Inc. - Common Stock last traded?
The last trade of Cybin Inc. - Common Stock was at 09/28/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.